Bms 582664
Also known as: Unii-U2Y5ofn795
It is an investigational, anti-tumorigenic drug for oral administration. The drug is being developed by Bristol-Myers Squibb for the treatment of hepatocellular carcinoma or HCC (also called malignant hepatoma), the most common type of liver cancer. Hepatocellular carcinoma is a primary cancer of the liver and is more common in men than in women. The disease occurs mostly in people who have scarring of the liver (cirrhosis) or after infection with hepatitis B or hepatitis C. Symptoms include pain and swelling in the abdomen, weight loss, weakness, loss of appetite and nausea. Hepatocellular carcinoma is a severe and life-threatening disease that is associated with poor overall survival. [2] While the choice of treatment depends mainly on how advanced the disease is, the only proven therapies to cure the cancer is surgery to remove the tumor and liver transplantation, but these therapies can only be carried out in very few patients. Other treatments include chemotherapy andimmunotherapy. Radiofrequency ablation and ethanol injection are also used to remove small tumors.
| Payment & Shipping Terms | Supply Capacity | ||
|---|---|---|---|
| Payment Terms: | T/T, WU | Production Capacity: | 1000kg/year |
| Min. Order: | 1 Gram | Packing: | according to the customer's requirements |
| Means of Transport: | Ocean, Air, Land | Delivery Date: | 7 days |
Bms 582664
CAS 649735-63-7
It is an investigational, anti-tumorigenic drug for oral administration. The drug is being developed by Bristol-Myers Squibb for the treatment of hepatocellular carcinoma or HCC (also called malignant hepatoma), the most common type of liver cancer. Hepatocellular carcinoma is a primary cancer of the liver and is more common in men than in women. The disease occurs mostly in people who have scarring of the liver (cirrhosis) or after infection with hepatitis B or hepatitis C. Symptoms include pain and swelling in the abdomen, weight loss, weakness, loss of appetite and nausea. Hepatocellular carcinoma is a severe and life-threatening disease that is associated with poor overall survival. [2] While the choice of treatment depends mainly on how advanced the disease is, the only proven therapies to cure the cancer is surgery to remove the tumor and liver transplantation, but these therapies can only be carried out in very few patients. Other treatments include chemotherapy andimmunotherapy. Radiofrequency ablation and ethanol injection are also used to remove small tumors.
We can customize according to customer's requirement
if you have any question pls mail us or call us.
| CAS Number | 649735-63-7 |
|---|---|
| Molecular Formula | C22H24FN5O4 |
| Molecular Weight | 441.46 |
| Place of Origin | Shandong,China (Mainland) |
| Content | 98% |
| Specification | CP/USP/EP |
Send an inquiry for Bms 582664
Related products
1-Bromo-3-chloro-2-methylpropane
Application:Used as pharmaceutical intermediates
1-benzyl-2-phenyl-1H-imidazole
Contact MOSINTER for product specifications and supply information.
10-Hydroxycamptothecin
Exemestane is an irreversible steroidal aromatase inhibitors, has similar structure with its substrate,natural androstenedione. And it is the pseudo substrate of aromatase . The inhibition of aromatase to estrogen deprivation is a effective method in the treatment of postmenopausal women with hormone dependent breast cancer.
2-Chlorophenothiazine
Application:Chlorpromazine hydrochloride used as drug intermediates; Pharmaceutical intermediates for the preparation of chlorpromazine, perphenazine.
3-Dimethylamino-2-methylpropyl Chloride Hydrochloride
Application:Used as pharmaceutical intermediates
3-Dimethylaminopropylchloride Hydrochloride
1. Used for synthesis of chlorpromazine, doxepin hydrochloride, chlorprothixene medicine, etc
3-Ethyl-4-methyl-3-pyrrolin-2-one
3-Ethyl-4-methyl-3-pyrrolin-2-one, a five-membered α,β-unsaturated lactam derivative, has various applications in medicinal chemistry. It can be synthesized by employing following as starting materials:[1] • allylamine, via palladium(II)-assisted cyclization • 4-methoxybenzylamine, via a ring-closing-metathesis strategy • 3-ethyl-1-(4-methoxybenzyl)-4-methyl-1,5-dihydro-2H-pyrrol-2- one
5- 1-Hydroxyl-1-methylethyl -2-propyl-imidazol-4-yl Carboxylic Acid Ethyl Ester
[5-(1-Hydroxyl-1-methylethyl)-2-propyl-imidazol-4-yl]carboxylic acid ethyl ester
